Benzinga | Sep 22, 2021 12:29PM EDT

Aegis Capital Maintains Buy on Cidara Therapeutics, Lowers Price Target to $8

Aegis Capital analyst Nathan Weinstein maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and lowers the price target from $9 to $8.